MANDALMED, INC.

Address

665 3rd Street
Suite 250
SAN FRANCISCO, CA, 94107-1953

http://www.mandalmed.com

Information

DUNS: 031636660
# of Employees: 4

Ownership Information

Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: Y

Award Charts




Award Listing

  1. Inhibition of Galectin-3 for Therapy of Remodeling After Myocardial Infarction

    Amount: $807,969.00

    The overall goal of this project is to develop a human protein that is an inhibitor of galectin as a biologic to aid in the prevention and treatment of harmful remodeling after myocardial infarctio ...

    SBIRPhase II2017Department of Health and Human Services National Institutes of Health
  2. Inhibition of Galectin-3 for Therapy of Remodeling After Myocardial Infarction

    Amount: $224,734.00

    PROJECT SUMMARY ABSTRACT The overall goal of this project is to develop a human protein that is an inhibitor of galectin as a biologic to aid in the prevention and treatment of harmful remodeling a ...

    SBIRPhase I2016Department of Health and Human Services
  3. Protein inhibitor of galectin-3 to limit fibrosis after myocardial infarction

    Amount: $299,958.00

    DESCRIPTION (provided by applicant): The wound-healing response of the human body to injuries involves induction of fibrosis, which is a dynamic scarring process. When fibrosis occurs in internal orga ...

    SBIRPhase I2013Department of Health and Human Services
  4. Model of the Human Testis for Reproductive Toxicology

    Amount: $250,000.00

    DESCRIPTION (provided by applicant): More than 87,000 chemicals have been developed and distributed over the past 50 years. The vast majority of these have not been tested for potential toxic effects ...

    SBIRPhase I2011Department of Health and Human Services
  5. Preclinical Testing of Galectin-3C for Multiple Myeloma

    Amount: $363,936.00

    DESCRIPTION (provided by applicant): The overall goal is development of a novel human protein, Galectin-3C, as a treatment for multiple myeloma (MM) that can be given with other agents to increase the ...

    SBIRPhase I2008Department of Health and Human Services
  6. Human Sertoli Cell Model for Study of Male Reproductive Function and Toxicity

    Amount: $255,200.00

    DESCRIPTION (provided by applicant): The overall goal of the Phase I research is to develop a three-dimensional model of the blood-testis barrier (BTB) consisting of primary human Sertoli cells cultur ...

    SBIRPhase I2007Department of Health and Human Services
  7. NO-donor/SOD-mimetics for diabetic nephropathy

    Amount: $134,000.00

    DESCRIPTION (provided by applicant): Vascular disease is the principal cause of morbidity and mortality in patients with diabetes, leading to nephropathy, retinopathy, neuropathy, and ischemic disease ...

    SBIRPhase I2005Department of Health and Human Services
  8. Novel Ex Vivo Gene Therapy for Spinal Cord Injury

    Amount: $749,980.00

    DESCRIPTION (provided by applicant): There are approximately 10,000 traumatic spinal cord injuries in the United States each year. The average age of injury is 31 years. The majority (90%) of individu ...

    SBIRPhase II2003Department of Health and Human Services
  9. NOVEL EX VIVO GENE THERAPY FOR SPINAL CORD INJURY

    Amount: $155,695.00

    DESCRIPTION (provided by applicant): The goal of the Phase I research is to develop ex vivo gene therapy that will achieve long-term, localized delivery of human neurotrophin-3 (hNT-3) i ...

    SBIRPhase I2002Department of Health and Human Services
  10. Novel Treatment for Breast Cancer: Truncated Galectin-3

    Amount: $236,893.00

    DESCRIPTION (provided by applicant): Despite the available treatments breast cancer ranks second as the cause of death from cancer in women pri ...

    SBIRPhase I2001Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government